Fibrillar Amyloid Protein Present in Atheroma Activates CD36 Signal Transduction*

The self-association of proteins to form amyloid fibrils has been implicated in the pathogenesis of a number of diseases including Alzheimer's, Parkinson's, and Creutzfeldt-Jakob diseases. We recently reported that the myeloid scavenger receptor CD36 initiates a signaling cascade upon binding to fibrillar β-amyloid that stimulates recruitment of microglia in the brain and production of inflammatory mediators. This receptor plays a key role in the pathogenesis of atherosclerosis, prompting us to evaluate whether fibrillar proteins were present in atherosclerotic lesions that could initiate signaling via CD36. We show that apolipoprotein C-II, a component of very low and high density lipoproteins, readily forms amyloid fibrils that initiate macrophage inflammatory responses including reactive oxygen production and tumor necrosis factor α expression. Using macrophages derived from wild type and Cd36-/- mice to distinguish CD36-specific events, we show that fibrillar apolipoprotein C-II activates a signaling cascade downstream of this receptor that includes Lyn and p44/42 MAPKs. Interruption of this signaling pathway through targeted deletion of Cd36 or blocking of p44/42 MAPK activation inhibits macrophage tumor necrosis factor α gene expression. Finally, we demonstrate that apolipoprotein C-II in human atheroma co-localizes to regions positive for markers of amyloid and macrophage accumulation. Together, these data characterize a CD36-dependent signaling cascade initiated by fibrillar amyloid species that may promote atherogenesis.

[1]  R. Clarke,et al.  Antioxidant Vitamins and Risk of Cardiovascular Disease. Review of Large-Scale Randomised Trials , 2002, Cardiovascular Drugs and Therapy.

[2]  Jonathan A. Jones,et al.  The circularization of amyloid fibrils formed by apolipoprotein C-II. , 2003, Biophysical journal.

[3]  S. Horiuchi,et al.  Class B Scavenger Receptors CD36 and SR-BI Are Receptors for Hypochlorite-modified Low Density Lipoprotein* , 2003, Journal of Biological Chemistry.

[4]  K. Moore,et al.  CD36 Mediates the Innate Host Response to β-Amyloid , 2003, The Journal of experimental medicine.

[5]  Douglas R. McDonald,et al.  A Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation , 2003, The Journal of Neuroscience.

[6]  Siamon Gordon,et al.  Pattern Recognition Receptors Doubling Up for the Innate Immune Response , 2002, Cell.

[7]  K. Moore,et al.  Scavenger Receptors Class A-I/II and CD36 Are the Principal Receptors Responsible for the Uptake of Modified Low Density Lipoprotein Leading to Lipid Loading in Macrophages* , 2002, The Journal of Biological Chemistry.

[8]  K. Moore,et al.  A CD36-initiated Signaling Cascade Mediates Inflammatory Effects of β-Amyloid* , 2002, The Journal of Biological Chemistry.

[9]  G. Howlett,et al.  Cross-linking and amyloid formation by N- and C-terminal cysteine derivatives of human apolipoprotein C-II. , 2002, Biochemistry.

[10]  S. Hazen,et al.  A Novel Family of Atherogenic Oxidized Phospholipids Promotes Macrophage Foam Cell Formation via the Scavenger Receptor CD36 and Is Enriched in Atherosclerotic Lesions* , 2002, Journal of Biological Chemistry.

[11]  D. Mangelsdorf,et al.  Regulated Expression of the Apolipoprotein E/C-I/C-IV/C-II Gene Cluster in Murine and Human Macrophages , 2002, The Journal of Biological Chemistry.

[12]  A. Tedgui,et al.  Platelets in atherosclerosis: a new role for beta-amyloid peptide beyond Alzheimer's disease. , 2002, Circulation research.

[13]  G. D. De Meyer,et al.  Platelet Phagocytosis and Processing of &bgr;-Amyloid Precursor Protein as a Mechanism of Macrophage Activation in Atherosclerosis , 2002, Circulation research.

[14]  D. Steinberg,et al.  Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis?: Do the Antioxidant Trials Conducted to Date Refute the Hypothesis? , 2002, Circulation.

[15]  A. Minton,et al.  Macromolecular Crowding Accelerates Amyloid Formation by Human Apolipoprotein C-II* , 2002, The Journal of Biological Chemistry.

[16]  R. Wetzel,et al.  Conformational Abs recognizing a generic amyloid fibril epitope , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Berman,et al.  CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. , 2002, The American journal of pathology.

[18]  S. Lindgren,et al.  C-terminal fragment of alpha1-antitrypsin activates human monocytes to a pro-inflammatory state through interactions with the CD36 scavenger receptor and LDL receptor. , 2001, Atherosclerosis.

[19]  M. Eulitz,et al.  Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis. , 2001, Biochemical and biophysical research communications.

[20]  K. Sletten,et al.  Apolipoprotein A‐1‐derived amyloid in atherosclerotic plaques of the human aorta , 2001, The Journal of pathology.

[21]  P. Westermark,et al.  Apolipoprotein A-I-derived amyloid in atherosclerosis. Its association with plasma levels of apolipoprotein A-I and cholesterol. , 2001, American journal of clinical pathology.

[22]  D. Altshuler,et al.  The role of PPAR-γ in macrophage differentiation and cholesterol uptake , 2001, Nature Medicine.

[23]  W. Dichtl,et al.  The carboxyl-terminal fragment of alpha1-antitrypsin is present in atherosclerotic plaques and regulates inflammatory transcription factors in primary human monocytes. , 2000, Molecular cell biology research communications : MCBRC.

[24]  C. MacPhee,et al.  Human apolipoprotein C-II forms twisted amyloid ribbons and closed loops. , 2000, Biochemistry.

[25]  S. Hazen,et al.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. , 2000, The Journal of clinical investigation.

[26]  S. Hazen,et al.  Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. , 2000, The Journal of clinical investigation.

[27]  T. Mazzone,et al.  Apolipoprotein E-dependent cholesterol efflux from macrophages: kinetic study and divergent mechanisms for endogenous versus exogenous apolipoprotein E. , 1999, Journal of lipid research.

[28]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[29]  M. Ferguson,et al.  Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. , 1998, Circulation.

[30]  C. S. Wang,et al.  Isolation and characterization of recombinant human apolipoprotein C-II expressed in Escherichia coli. , 1996, Biochimica et biophysica acta.

[31]  K. Sletten,et al.  Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. , 1995, The American journal of pathology.

[32]  M. Lalowski,et al.  Is Alzheimer's disease an apolipoprotein E amyloidosis? , 1995, The Lancet.

[33]  T. Wisniewski,et al.  Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. , 1995, The American journal of pathology.

[34]  T. Rademacher,et al.  Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Kitagawa,et al.  Polymorphism of apolipoprotein A-II (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis. , 1991, The Biochemical journal.

[36]  S. Schwartz,et al.  Cell proliferation in human coronary arteries. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Gown,et al.  Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. , 1986, The American journal of pathology.

[38]  G. Coetzee,et al.  Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. , 1986, The Journal of biological chemistry.

[39]  R. Jackson,et al.  Isolation and properties of human apolipoproteins C-I, C-II, and C-III. , 1986, Methods in enzymology.

[40]  M. Spector,et al.  Structural properties and lipid binding of human apolipoprotein A-IV. , 1985, The Journal of biological chemistry.

[41]  R. Havel,et al.  Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources. , 1973, Biochemistry.